Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House FDA drug reform bill may be most viable to patient groups -- AIDS patient rep.

This article was originally published in The Tan Sheet

Executive Summary

HOUSE FDA DRUG REFORM BILL POTENTIALLY MORE ACCEPTABLE TO PATIENTS GROUPS than the Senate FDA reform legislation, AIDS Action Council representative Gary Rose indicated July 2. At a press conference organized with Public Citizen, representatives of the American Foundation for AIDS Research, AIDS Action Council, the National Organization for Rare Disorders and the National Council on Aging criticized the recently filed committee report on Sen. Nancy Kassebaum's (R-Kan.) FDA reform proposal (S 1477).
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel